Materials Science Program, Department of Biomedical Engineering, University of Wisconsin-Madison, 1550 Engineering Dr., no. 2152, Madison, WI 53706, USA.
Am J Physiol Heart Circ Physiol. 2011 Feb;300(2):H448-58. doi: 10.1152/ajpheart.01178.2009. Epub 2010 Dec 3.
The differentiation of valvular interstitial cells (VICs) to a myofibroblastic or osteoblast-like phenotype is commonly found in calcific valvular stenosis, although the molecular-level mechanisms of this process remain poorly understood. Due to the role of the Rho pathway in various vascular diseases and in the expression of a myofibroblast phenotype, the present study was inspired by the hypothesis that Rho activation is involved in regulating cellular processes related to valve calcification. It was found that increased RhoA and Rho kinase (ROCK) activity was associated with increased nodule formation in VIC cultures in vitro, and intentional induction of RhoA activity led to a further increase in nodules and expression of α-smooth muscle actin. VICs treated with ROCK inhibitors were also examined for nodule formation, proliferation, apoptosis, and expression of myofibroblastic or osteoblastic markers. ROCK inhibition dramatically reduced myofibroblast-regulated nodule formation in VIC cultures, as evidenced by a decrease in nodule number, total nodule area, α-smooth muscle actin-positive stress fibers, apoptosis, and gene expression of myofibroblast-related phenotypic markers. Meanwhile, ROCK inhibition was less effective at reducing nodule formation associated with osteogenic activity. In fact, ROCK inhibition increased the expression of alkaline phosphatase and effected only a modest decrease in nodule number when applied to VIC cultures with higher osteogenic activity. Thus, the Rho pathway possesses a complex role in regulating the VIC phenotype and nodule formation, and it is hoped that further elucidation of these molecular-level events will lead to an improved understanding of valvular disease and identification of potential treatments.
瓣膜间质细胞 (VIC) 向肌成纤维细胞或成骨样表型的分化在钙化性瓣膜狭窄中很常见,尽管这一过程的分子水平机制仍知之甚少。由于 Rho 通路在各种血管疾病和肌成纤维细胞表型表达中的作用,本研究的灵感来自 Rho 激活参与调节与瓣膜钙化相关的细胞过程的假设。研究发现,RhoA 和 Rho 激酶 (ROCK) 活性的增加与体外 VIC 培养物中结节形成的增加有关,并且 RhoA 活性的有意诱导导致结节和α-平滑肌肌动蛋白的表达进一步增加。还研究了用 ROCK 抑制剂处理的 VIC 形成结节、增殖、凋亡以及肌成纤维细胞或成骨细胞标志物的表达。ROCK 抑制显著减少了 VIC 培养物中肌成纤维细胞调节的结节形成,这表现在结节数量、总结节面积、α-平滑肌肌动蛋白阳性应激纤维、凋亡以及肌成纤维细胞相关表型标志物的基因表达减少。同时,ROCK 抑制在减少与成骨活性相关的结节形成方面效果较差。事实上,ROCK 抑制增加了碱性磷酸酶的表达,当应用于具有更高成骨活性的 VIC 培养物时,仅使结节数量适度减少。因此,Rho 通路在调节 VIC 表型和结节形成方面具有复杂的作用,希望进一步阐明这些分子水平事件将有助于更好地理解瓣膜疾病并确定潜在的治疗方法。